Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates

~ Advancing FDA interactions on AMT-130 for Huntington's disease; Type B meeting scheduled for the second quarter of 2026 ~

uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington's Disease

~ Submission of a UK Marketing Authorization Application for AMT-130 is expected  in the third quarter of 2026 ~

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 13, 2026 in uniQure N.V. Lawsuit – QURE

NEW YORK, April 13, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in uniQure N.V. ("uniQure" or the "Company") (NASDAQ: QURE) of a class action securities lawsuit.

Bronstein, Gewirtz & Grossman LLC Urges uniQure N.V. Investors to Act: Class Action Filed Alleging Investor Harm

New York, New York--(Newsfile Corp. - April 13, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against uniQure N.V. (NASDAQ: QURE) and certain of its officers.